1. Uno Minda: 

Axis Direct upgrades this auto parts producer to a ‘Buy’ rating from ‘Hold’, with a target price of Rs 1,260 per share, a 22.1% upside. The impact of the US-Iran war is negative for the company in the short-to-medium term. The closure of the Strait of Hormuz and rising regional instability affect global logistics, raw material costs, and the European market, which is a key export destination for the company. Its stock price declined 13.2% over the past month.

Analyst Sanchit Kumar, however, sees strong long-term growth for the company, driven by new product launches, premiumisation, ongoing capacity expansion, and a robust EV order book. Uno Minda is also well-positioned to profit from stricter safety and acoustic regulations.

As India's top automotive horn maker and second globally, the company benefits from mandated Acoustic Vehicle Alerting Systems (AVAS) in EVs, recently securing orders in the electric passenger vehicle segment. Its airbag joint venture is building a new Rs 280 crore facility in Karnataka to meet the rising demand for vehicle safety features.

Through its 76% stake in the Minda Westport joint venture, the company also makes CNG and LPG kits, profiting directly from the surge in CNG vehicle sales. Kumar believes ongoing investments, a focus on making more parts locally, and strong demand at home will fuel its growth.

2. Power Grid Corp of India: 

Prabhudas Lilladher maintains its ‘Buy’ call on this electric utilities provider, with a target price of Rs 324 per share, an upside of 17.5%. Analysts Vishal Periwal and Shubham Shelar believe Power Grid is perfectly placed to seize India’s massive Rs 15 lakh crore transmission opportunity. This translates to a potential annual order pipeline of Rs 60,000–70,000 crore.

The company is consolidating 19 special purpose vehicles (SPVs) into two, with more mergers planned. Analysts note that this move will streamline governance, improve capital allocation, and boost scalability as Power Grid's asset base grows. Management approved a capex of Rs 37,000 crore for FY27 and Rs 45,000 crore for FY28. They expect further upside from new project wins and strong execution.

Periwal and Shelar say that the company's right-of-way (ROW) challenges have eased. The government introduced a market-linked compensation framework to improve land acquisition. Clearer guidelines have also reduced disputes, and the company has strengthened execution with dedicated ROW teams and specialised expertise. They expect Power Grid to achieve a 9.8% revenue CAGR and a 5.9% net profit CAGR through FY28.

3. Sky Gold and Diamonds: 

BOB Capital Markets initiates coverage on this small-cap jewellery manufacturer with a ‘Buy’ call and a target price of Rs 494 per share, an upside of 55.2%. The stock fell 11.9% last month. The Israel–Iran war poses a risk, as Middle East exports, about 10% of revenue, face potential shipping delays and higher costs. Analyst Lavita Lasrado still likes the company, pointing to strong growth in its B2B model where Sky Gold supplies gold jewellery to retail chains without owning its stores. This asset-light strategy keeps costs low and allows for efficient expansion.

Management reports that capacity has surged to over 1,000 kg per month, yet utilisation sits at a low 33–46%. This offers significant room for volume growth without major new spending. Sky Gold is also shifting its product mix towards higher-margin items like 18-carat studded and diamond jewellery, which now form about 25% of its offerings. Growth comes from deeper client relationships, new retailer tie-ups, export expansion, and selective acquisitions that strengthen manufacturing capabilities.

Analyst Lavita Lasrado expects revenue to grow at around 37% CAGR over FY26–28, driven by volume ramp-up and new clients. EBITDA margins should improve to around 6.5%, supported by a better product mix and operating leverage. However, the analyst identifies client concentration as a key risk, with a significant share of revenue coming from top customers.

4. Aurobindo Pharma:

Motilal Oswal retains its ‘Buy’ rating on this pharmaceutical manufacturer, with a target price of Rs 1,500 per share, an upside of 15%. Analysts Tushar Manudhane and Vipul Mehta believe several factors will boost future earnings: scaling up the Penicillin-G (Pen-G) plant, increased external sales of 6-Amino Penicillanic Acid (6-APA), higher demand in the EU, new US product launches, and integrating Lannett (US-based generics manufacturer).

Aurobindo makes 6-APA, which is a key ingredient in antibiotics like amoxicillin, ampicillin, and piperacillin. To support this, the company has set up a Penicillin-G (Pen-G) plant, which started operations in July 2025 and is now gradually increasing output. The 6-APA plant is also expected to reach full capacity in the next 3–4 months.

Manudhane and Mehta add that from the planned 15,000 metric tonnes (MT) of Pen-G, 3,000 MT goes to domestic sales. They use the remaining 12,000 MT of Pen-G to produce 6-APA. By producing these inputs in-house instead of buying them, Aurobindo reduces costs and improves control over its supply chain, giving it an advantage over competitors. They expect the company to achieve a 9% revenue CAGR and a 21% net profit CAGR from FY26-28.

5. Sagility:

ICICI Securities reiterates its ‘Buy’ rating on this business service provider, with a target price of Rs 66 per share, an upside of 65.2%. AI's growing use in healthcare outsourcing drives this positive outlook. Sagility operates in the US healthcare market, where low outsourcing offers a significant long-term opportunity. High client stickiness, with 97% retention and an 18-year average tenure, ensures steady growth.

Management states AI expands their work, rather than shrinking it. The company is moving from traditional employee-based models to outcome-based pricing, guaranteeing clients cost savings. Sagility uses AI across key areas like claims processing, payment integrity, revenue cycle management, and utilisation management to boost efficiency and cut costs. New growth opportunities exist in medical loss ratio management, appeals, and clinical services, representing a significant $20,000–32,000 crore market.

Analysts Ruchi Mukhija and Seema Nayak expect strong growth, supported by AI-led solutions and expansion into new service areas. EBITDA margins should remain stable at 24–25%. They add that US healthcare demand will keep growing, fueled by the popularity of GLP-1 drugs used for obesity and diabetes, higher healthcare activity and long-term outsourcing growth.

Note: These recommendations are from various analysts and are not recommendations by Trendlyne.

(You can find all analyst picks here)